Grace Therapeutics (GRCE)

• Market cap: $34.2M
• 1 day: 0.45%
• 5 days: -3.9%
• 1 month: 2.3%
• 3 months: -49.77%
• 6 months: -33.53%
• Year to date: -39.34%
• 1 year: -23.18%
• 5 years: -91.24%
• 10 years: -96.92%
• Sector: Healthcare
• Industry: Biotechnology

About: Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.

Employees: 6